摘要
目的：从基因水平探讨精神分裂症患者对利培酮的临床治疗效应存在个体差异的原因。方法：对79名精神分裂症患者进行为期6周的利培酮治疗，评价临床疗效，同时就5-HT2A受体基因启动子区域-1438G/A多态位点进行基因型和等位基因频率检测，据此分析基因型和等位基因频率与临床治疗效应的关系。 结果：受体-1438G/A的基因型和等位基因频率与利培酮的临床总体疗效有关(?2=13.60；P<0.01)， GG基因型或等位基因为G的患者临床疗效相对较差。结论：精神分裂症患者5-HT2A受体-1438G/A的基因型和等位基因可以作为利培酮临床疗效的预测因子。5-HT2A受体可能为非典型抗精神病药物作用的靶受体。
OBJECTIVE: To investigate the reasons at the molecular level why there are individual differences in the therapeutic response to risperidone in schizophrenic patients. METHODS: Seventy-nine schizophrenic in-patients were treated with risperidone for 6 weeks. The therapeutic effects of risperidone were assessed by Positive And Negative Syndrom Scale (PANSS). RESULTS: We genotyped the -1438G/A polymorphism of 5-HT2A receptor gene, and tried to find the association between genotype or alleles and Risperidone response. The genotype GG and allele G of -1438G/A were closely associated with poor risperidone response, whereas genotpye AA, AG and allele A are related to good response to risperidone on schizophrenia (P<0.01). CONCLUSION: The genotype and allele of -1438G/A of 5-HT2A receptor gene can be the predictors to risperidone efficacy. 5-HT2A receptor maybe the therapeutic target of atypical antipsychotics.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2000年第5期353-355,共3页
The Chinese Journal of Clinical Pharmacology
